Skip to main content

AbbVie vs Johnson & Johnson: Founders, CEOs and History

AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, Edward Mead Johnson and is led by Joaquin Duato.

Company facts

AbbVie

Founded
2013
Headquarters
North Chicago, Illinois
Current CEO
Robert A. Michael
Employees
57,000

Johnson & Johnson

Founded
1886
Headquarters
New Brunswick, New Jersey
Current CEO
Joaquin Duato
Employees
140,800

Founders

AbbVie

  • Abbott Laboratories (spin-off origin)

    Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.

AbbVie founders in full

Johnson & Johnson

  • Robert Wood Johnson

    Robert Wood Johnson (1845-1910) co-founded Johnson & Johnson in 1886 and served as its first president.

  • James Wood Johnson

    James Wood Johnson (1856-1932) co-founded J&J with his brothers in 1886. An engineer by trade, he designed the early manufacturing machinery that allowed the company to mass-produce sterile surgical dressings.

  • Edward Mead Johnson

    Edward Mead Johnson (1852-1934) co-founded J&J in 1886, bringing crucial sales and marketing expertise to the early business.

Johnson & Johnson founders in full

CEOs and their tenures

AbbVie

  1. Richard A. Gonzalez2013–2024

    Founding Chairman and Chief Executive Officer

    Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.

    Source
  2. Robert A. Michael2024–present

    Chairman and Chief Executive Officer

    Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.

    Source
AbbVie CEO history in full

Johnson & Johnson

  1. Ralph Larsen1989–2002

    Former Chairman and Chief Executive Officer

    Larsen's acquisitions, including Neutrogena, Cordis, DePuy, and Centocor, broadened J&J into medical devices and biologics, laying groundwork for today's MedTech segment and immunology franchise.

    Source
  2. William Weldon2002–2012

    Former Chairman and Chief Executive Officer

    Weldon's later years were overshadowed by a wave of consumer product recalls, including Tylenol and Motrin, tied to manufacturing-quality problems.

    Source
  3. Alex Gorsky2012–2022

    Former Chairman and Chief Executive Officer

    Gorsky's tenure set up the 2023 Kenvue separation completed under his successor and saw J&J's single-dose COVID-19 vaccine authorized in 2021. He also oversaw the $30 billion Actelion acquisition in 2017 and the early years of talc litigation.

    Source
  4. Joaquin Duato2022–present

    Chairman and Chief Executive Officer

    Under Duato, J&J's sales reached $94.193 billion in FY2025 with $26.804 billion in net earnings, and the company guides to its first $100 billion year in 2026. He also launched the DePuy Synthes separation and the 2026 talc settlement proposal.

    Source
Johnson & Johnson CEO history in full

Timeline: AbbVie and Johnson & Johnson side by side

  1. 1886Johnson & Johnson

    Johnson & Johnson Founded

    Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson found the company in New Brunswick, New Jersey, with 14 employees, to mass-produce sterile surgical dressings after Robert was inspired by antiseptic pioneer Joseph Lister's 1885 warnings about i…

  2. 1920Johnson & Johnson

    Band-Aid Brand Adhesive Bandages Introduced

    J&J introduces the first mass-produced adhesive bandage, sold under the Band-Aid brand starting in 1921; it becomes one of the most recognized consumer-health brands in the world before J&J later spins its consumer division out as Kenvue in 2023.

  3. 1943Johnson & Johnson

    Robert Wood Johnson II Writes 'Our Credo'

    Chairman Robert Wood Johnson II authors 'Our Credo,' a one-page statement ranking the company's responsibilities to customers, employees, communities, and shareholders in that order; it remains J&J's official governing philosophy and was later cited as the bas…

  4. 1944Johnson & Johnson

    J&J Goes Public

    Johnson & Johnson lists publicly, becoming an independent, market-traded company as it expands into a diversified healthcare business under Chairman Robert Wood Johnson II.

  5. 1982Johnson & Johnson

    Tylenol Cyanide Poisonings and Nationwide Recall

    After seven people in the Chicago area die from cyanide-laced Extra-Strength Tylenol capsules, J&J issues a nationwide recall of 31 million bottles within a week -- far beyond what investigators said was necessary -- citing Our Credo's customer-safety priority…

  6. 2012Johnson & Johnson

    Alex Gorsky Becomes CEO

    Gorsky succeeds William Weldon as CEO amid a period of manufacturing-quality recalls, and spends the next decade restoring J&J's operational reputation while expanding the pharmaceutical and MedTech businesses and developing a single-dose COVID-19 vaccine duri…

  7. 2013AbbVie

    AbbVie Launches as an Independent Company

    AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.

  8. 2015AbbVie

    Pharmacyclics Acquisition Completed

    AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.

  9. 2017Johnson & Johnson

    Actelion Acquired

    Johnson & Johnson bought the Swiss drugmaker Actelion in 2017 for about $30 billion.

  10. 2019AbbVie

    Skyrizi Receives Initial U.S. Approval

    The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.

  11. 2019AbbVie

    Rinvoq Receives Initial U.S. Approval

    The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.

  12. 2020AbbVie

    Allergan Acquisition Completed

    AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.

  13. 2022Johnson & Johnson

    Joaquin Duato Becomes CEO

    Duato becomes CEO in January 2022, later adding the chairman title, and begins preparing the separation of J&J's consumer-health business from its medicine and device operations.

  14. 2023AbbVie

    U.S. Humira Biosimilar Competition Begins

    Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.

  15. 2023Johnson & Johnson

    Kenvue Separation

    J&J completes the spinoff of its consumer-health business (Band-Aid, Tylenol, Listerine, Neutrogena) as the standalone public company Kenvue, narrowing J&J around its higher-margin Innovative Medicine and MedTech segments.

  16. 2024AbbVie

    ImmunoGen Acquisition Completed

    AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.

  17. 2024AbbVie

    Robert A. Michael Becomes CEO

    Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.

  18. 2024AbbVie

    Cerevel Therapeutics Acquisition Completed

    AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.

  19. 2025AbbVie

    Robert A. Michael Becomes Chairman

    Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.

  20. 2025AbbVie

    FY2025 Revenue Reaches $61.160 Billion

    AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.

  21. 2025Johnson & Johnson

    FY2025 Sales of $94.193B

    Johnson & Johnson reports $94.193 billion in sales and $26.804 billion in net earnings, split roughly 64% Innovative Medicine and 36% MedTech, both segments growing about 6% year over year.

  22. 2025Johnson & Johnson

    Orthopaedics Separation Announced

    In October 2025 J&J announced plans to separate its orthopaedics business as a standalone company operating as DePuy Synthes, targeting completion in 2027.

  23. 2026AbbVie

    Q1 2026 Revenue Reaches $15.002 Billion

    AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.

  24. 2026Johnson & Johnson

    Proposed Talc Resolution and Raised Guidance

    J&J raised 2026 sales guidance to about $101.1 billion after Q2 sales of $25.31 billion, and on July 27, 2026 proposed an estimated $5.5 billion resolution of remaining ovarian talc claims.

Acquisitions

AbbVie

  • ImmunoGen, Inc.2024$10.1B
  • Cerevel Therapeutics2024$8.7B
  • Allergan plc2020$63B
  • Pharmacyclics, Inc.2015$21B
All AbbVie acquisitions

Johnson & Johnson

  • Intra-Cellular Therapies2025$14.6B
  • Shockwave Medical2024$13.1B
  • Kenvue separation2023Undisclosed
  • Abiomed2022$16.6B
  • Actelion2017$30B
All Johnson & Johnson acquisitions

Questions about AbbVie vs Johnson & Johnson

Who is the CEO of AbbVie Inc. and Johnson & Johnson?

AbbVie Inc. is led by Robert A. Michael and Johnson & Johnson is led by Joaquin Duato. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was AbbVie Inc. founded vs Johnson & Johnson?

Johnson & Johnson was founded in 1886 — 127 years before AbbVie Inc., which was founded in 2013. Johnson & Johnson's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..

How many employees does AbbVie Inc. have compared to Johnson & Johnson?

AbbVie Inc. employs approximately 57,000 people, while Johnson & Johnson employs approximately 140,800. Johnson & Johnson has the larger workforce at 140,800 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are AbbVie Inc. and Johnson & Johnson headquartered?

Both AbbVie Inc. and Johnson & Johnson are headquartered in United States. Their local rules and tax obligations may still differ.

Who founded AbbVie Inc. and Johnson & Johnson?

AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Johnson & Johnson was founded by Robert Wood Johnson, James Wood Johnson, Edward Mead Johnson.

Which company has a longer operating history — AbbVie Inc. or Johnson & Johnson?

Johnson & Johnson has been operating for approximately 140 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Johnson & Johnson overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.